• Revenue up 56% to $5.9m, driven by 89.5% growth in Software-as-a-Service (SaaS)
• Other income of $10.6m from government grants and R&D tax incentive
• Net loss reduced by 16% to $30.1m, reflecting increased commercialisation investment

4DMEDICAL Ltd has reported its preliminary financial results for the year ended 30 June 2025. The company's operating revenue was $5.9m, up 56% on the prior corresponding period (FY2024: $3.8m). This revenue was principally related to Software-as-a-Service (SaaS), which grew 89.5% to $5.7m, with the remainder coming from lease and maintenance income. 4DMEDICAL also received $10.6m in other income, reflecting government grants, including from the Medical Research Future Fund (MRFF) and the Cooperative Research Centres Projects (CRC-P) program, as well as its R&D tax incentive payment. The company reported a net loss of $30.1m, down 16% from the prior year, despite increased investment in commercialisation activities, offset by reductions in consultancy, travel and clinical trial expenditure. 4DMEDICAL ended the year with $6.9m in cash and cash equivalents.

For the financial year ending 30 June 2026, 4DMEDICAL expects to continue its strong growth trajectory, with further expansion of its Software-as-a-Service (SaaS) revenue and additional government grant funding to support the development and commercialisation of its XV Scanner technology.